Patents Assigned to Rhizen Pharmaceuticals SA
  • Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
    Patent number: 11065236
    Abstract: This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: July 20, 2021
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. Vakkalanka, Srikant Viswanadha
  • 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
    Patent number: 11066402
    Abstract: The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: July 20, 2021
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. V. S. Vakkalanka, Dhanapalan Nagarathnam, Srikant Viswanadha, Meyyappan Muthuppalaniappan, Govindarajulu Babu, Prashant K. Bhavar
  • Intermediates useful in the synthesis of compounds as modulators of protein kinases
    Patent number: 11020399
    Abstract: The present invention provides compounds of formula (10), formula (12), formula (14) and formula (15) wherein R, R1, R2, Cy1 and X are as described herein.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: June 1, 2021
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
  • Selective PI3K delta inhibitors
    Patent number: 10981919
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 20, 2021
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
    Patent number: 10966977
    Abstract: Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 6, 2021
    Assignees: TG Therapeutics, Inc., Rhizen Pharmaceuticals SA, Laboratoire Francais du Fractionnement et das Biotechnologies
    Inventors: Michael S. Weiss, Hari P. Miskin, Peter Sportelli
  • Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
    Patent number: 10947244
    Abstract: The present invention relates to solid state forms of a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202). The present invention also relates to methods of preparing the same, pharmaceutical compositions containing them, and methods of treating a PI3K kinase mediated disease or disorder, such as cancer, by administering the same.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 16, 2021
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventor: Swaroop K. Vakkalanka
  • Dual selective P13 delta and gamma kinase inhibitors
    Patent number: 10851107
    Abstract: The present invention relates to dual delta (?) and gamma (?) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: December 1, 2020
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop K. Vakkalanka, Prashant K. Bhavar, Srikant Viswanadha, Govindarajulu Babu
  • Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid
    Patent number: 10786504
    Abstract: This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 29, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. V. S. Vakkalanka, Srikant Viswanadha
  • Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
    Patent number: 10729768
    Abstract: Highly effective combinations of a compound of formula A (a PI3K? selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K? and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 4, 2020
    Assignees: TG Therapeutics, Inc., Rhizen Pharmaceuticals SA, Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K. V. S. Vakkalanka
  • Modulators of calcium release-activated calcium channel
    Patent number: 10668051
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: June 2, 2020
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Gayatri S. Merikapudi, Swaroop K. Vakkalanka
  • Glutaminase inhibitors
    Patent number: 10611759
    Abstract: The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders involving glutamine.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: April 7, 2020
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Prashant K. Bhavar, Swaroop K. Vakkalanka, Srikant Viswanadha, Gayatri Swaroop Merikapudi, Govindarajulu Babu
  • 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases
    Patent number: 10590129
    Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 17, 2020
    Assignees: RHIZEN PHARMACEUTICALS SA, INCOZEN THERAPEUTICS PVT. LTD.
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
  • Selective PI3K delta inhibitors
    Patent number: 10570142
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: February 25, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Kinase modulators
    Patent number: 10538501
    Abstract: The present invention provides PI3K protein kinase modulators of Formula (I) wherein R, R1,R2,L1, Cy1 and Cy2 are as disclosed herein, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: January 21, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
  • 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases
    Patent number: 10442783
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: October 15, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop Kumar V. S. Vakkalanka
  • Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
    Patent number: 10414773
    Abstract: The present invention relates to solid state forms of a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202). The present invention also relates to methods of preparing the same, pharmaceutical compositions containing them, and methods of treating a PI3K kinase mediated disease or disorder, such as cancer, by administering the same.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 17, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventor: Swaroop K. Vakkalanka
  • Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
    Patent number: 10413532
    Abstract: This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 17, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop K. Vakkalanka, Srikant Viswanadha
  • Substituted chromenones as modulators of protein kinases
    Patent number: 10322130
    Abstract: The present invention provides PI3K protein kinase modulators of formula wherein R, Cy1, R1, R2, L1 and Cy2 are as defined herein. The present invention also relates to methods of preparing compounds of formula (I) to pharmaceutical compositions containing them and to methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 18, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
  • COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS
    Publication number: 20190175592
    Abstract: Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.
    Type: Application
    Filed: May 26, 2017
    Publication date: June 13, 2019
    Applicants: TG Therapeutics, Inc., Rhizen Pharmaceuticals SA, Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Michael S. WEISS, Hari P. MISKIN, Peter SPORTLLI
  • Modulators of calcium release-activated calcium channel
    Patent number: 10246450
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 2, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Gayatri S. Merikapudi, Swaroop K. Vakkalanka